Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide vs Insulin Glulisine in T2DM Insufficiently Controlled on Basal Insulin
NCT01768559Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2013
- Primary completion
- Dec 2014
- Modality
- Peptides
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of lixisenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoints: Change in HbA1c From Baseline to Week 26 and Change in Body Weight From Baseline to Week 26. Started Jan 2013; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01768559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01768559.